Pàgina d'iniciAVXT • OTCMKTS
add
AVAX Technologies Inc
0,00010 $
Preobertura:(99,00 %)-0,000099
0,00 $
Tancat: 12 d’abr., 16:24:34 GMT-4 · USD · OTCMKTS · Exempció de responsabilitat
Tancament anterior
0,00010 $
Capitalit. borsària
14,26 k USD
Volum mitjà
333,00
Ràtio PER
-
Rendibilitat per dividend
-
Borsa principal
OTCMKTS
Notícies dels mercats
Informació
Avax Technologies, Inc. is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate of 44% and response rate of 35%. Wikipedia
Data de fundació
1990
Seu principal
Lloc web
Empleats
29